BRILINTA Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting
- Details
- Category: AstraZeneca
AstraZeneca announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome (ACS) patients, those with ST Segment Elevation Myocardial Infarction (STEMI). In this setting, ST segment elevation indicates total obstruction of a coronary artery which warrants emergency surgery with angioplasty,
Sanofi-aventis and Regeneron expand strategic Antibody Collaboration
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies.
Novartis launches Prevacid® 24 HR over-the-counter
- Details
- Category: Novartis
Novartis announced the availability of Prevacid®24HR (lansoprazole delayed-release capsules 15 mg/acid reducer) over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn. Prevacid®24HR received US Food and Drug Administration (FDA) approval in May 2009.
Nycomed reports continued satisfactory performance in the third quarter 2009
- Details
- Category: Nycomed
Nycomed reports continued satisfactory performance in the third quarter 2009, with total net turnover increasing by 0.9% (3.2% in local currencies) to €820.0 million. Pantoprazole sales were resilient after losing patent protection in May in 12 European countries. On a regional basis, sales in most emerging markets exhibited strong growth. The pipeline portfolio advanced significantly.
Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.
FDA approves GSK's pandemic H1N1 vaccine
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that the US Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for its unadjuvanted influenza A (H1N1) pandemic vaccine.
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals, Inc., announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.
More Pharma News ...
- WHO Grants Prequalification for Global Use to GSK's 10-Valent Synflorix⢠Vaccine
- Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
- Novartis to expand its human vaccines presence in China
- New Merck Begins Operations
- World's largest malaria vaccine trial now underway in seven African countries
- Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China
- Pfizer and Medivation Initiate Two Phase 3 Trials of Dimebon